GMDA(Delisted)
Gamida Cell·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GMDA
Gamida Cell Ltd.
A company that develops cell therapies to cure cancer and rare, serious hematologic diseases
116 Huntington Avenue, 7th Floor, Boston, MA 02116
--
Gamida Cell Ltd. is an Israeli company established in 1998. The company is a pioneer in cell therapy, working to turn cells into powerful therapies. The company applies a proprietary extended platform utilizing the properties of nicotinamide to allogeneic cell sources, including cord blood-derived cells and natural killer cells, to create cell therapy candidates that may redefine the standard of care. The company's lead product candidate is omidubicel, an advanced cell therapy product candidate for allogeneic hematopoietic stem cell transplantation that, if approved, has the potential to expand treatment coverage and improve treatment outcomes for blood cancer patients.
Company Financials
EPS
GMDA has released its 2023 Q4 earnings. EPS was reported at 0.02, versus the expected -0.15, beating expectations. The chart below visualizes how GMDA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GMDA has released its 2023 Q4 earnings report, with revenue of 1.11M, reflecting a YoY change of NaN%, and net profit of -8.84M, showing a YoY change of 61.22%. The Sankey diagram below clearly presents GMDA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
